TNFRSF9 and cancer: In multiple immune cell subsets, TNFRSF9 (CD137) provides a costimulatory signal, suggesting that combination therapy comprising CD137 antibodies with therapeutic antibodies and/or vaccination might improve cancer treatment (42).